Who is sponsoring NCT03100695?

NCT03100695 is sponsored by University of Leeds.

What drugs are being tested in NCT03100695?

Interventions in NCT03100695: Concentrated autologous PRP-BMA.

What condition does NCT03100695 study?

NCT03100695 studies Unilateral Tibial Diaphyseal Fracture.

Is NCT03100695 still recruiting?

NCT03100695 is currently status unknown. Last updated 25 March 2021.

Last reviewed 2021-03-25 · How we verify

NCT03100695: T-PAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tibial Fracture - Platelet-rich Plasma and Bone Marrow Concentrate

Status unknown NA Last updated 25 March 2021

What this trial tests

NA trial testing Concentrated autologous PRP-BMA in Unilateral Tibial Diaphyseal Fracture in 45 participants. Status unknown.

Timeline

4 October 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	University of Leeds
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	45
Start date	4 October 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Concentrated autologous PRP-BMA

Conditions studied

Unilateral Tibial Diaphyseal Fracture — all drugs for Unilateral Tibial Diaphyseal Fracture →

Sponsor

University of Leeds

Who can join

Adults 18 to 65, any sex, with Unilateral Tibial Diaphyseal Fracture. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, randomised study is to investigate the feasibility of conducting a superiority randomised controlled trial comparing the application of combined autologous PRP and concentrated autologous bone marrow (PRP-BMA) in addition to standard of care (either reamed intramedullary nailing or fine wire ring external fixator) for patients presenting with fresh tibial diaphyseal fractures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Leeds trials

Trials by the same sponsor.

NCT07488143 — AI-assisted Continuous Stratification in Neurorehabilitation of Stroke Using Personalized Digital Twins · NA · not yet recruiting
NCT07409363 — Non-invasive Vagus Nerve Stimulation for Chronic Musculoskeletal Pain · NA · not yet recruiting
NCT07247812 — tSCS in Children and Young People With HCP · NA · not yet recruiting
NCT07181915 — Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits · NA · active not recruiting
NCT06240403 — Digoxin and Senolysis in Heart Failure and Diabetes Mellitus · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03100695 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Leeds
Last refreshed: 25 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing